Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Inflammatory Bowel Diseases

Free Subscription Articles published in Gastroenterol Hepatol Retrieve available abstracts of 124 articles: HTML format

Single Articles

April 2024
1. FUENTES-VALENZUELA E, Carbajo AY, Fernandez-Prada SJ, Rubiales BM, et al
   Beyond Crohn's disease: Deferasirox as possible agent for drug-induced ileocolitis.
   Gastroenterol Hepatol. 2024;47:380-381.
   PubMed    
   
   
   
2. RODRIGUEZ-LAGO I, Abecia L, Seoane I, Anguita J, et al
   An in vitro analysis of the interaction between infliximab and granulocyte-monocyte apheresis.
   Gastroenterol Hepatol. 2024;47:347-351.
   PubMed     Abstract available
   
   
   March 2024
3. NAVARRO-GERRARD C, Calafat M, Benitez JM, Suarez-Ferrer C, et al
   Are biologic agents effective and safe in patients with IBD and solid organ transplantation?
   Gastroenterol Hepatol. 2024;47:289-292.
   PubMed    
   
   
   
4. LASA J, Smolarczuk A, Navar S, Ponce C, et al
   Endoscopic scoring system utilization for inflammatory bowel disease activity assessment: A multicenter real-world study from Argentina.
   Gastroenterol Hepatol. 2024;47:253-261.
   PubMed     Abstract available
   
   
   February 2024
5. CALM A, Calafat M, Gonzalez-Munoza C, Canete F, et al
   Incidence of herpes zoster in patients with inflammatory bowel disease.
   Gastroenterol Hepatol. 2024 Feb 3:S0210-5705(24)00032.
   PubMed     Abstract available
   
   
   
6. VARA-LUIZ F, Mendes I, Teles AE, Oliveira C, et al
   Malignant transformation in fistula after proctosigmoidectomy: A rare complication of longstanding Crohn's Disease.
   Gastroenterol Hepatol. 2024 Feb 3:S0210-5705(24)00033.
   PubMed    
   
   
   
7. PARRA V, Cifuentes S, Avendano S, de Leon EP, et al
   Real-world experience of vedolizumab use in Colombian patients with inflammatory bowel disease-EXVEDOCOL.
   Gastroenterol Hepatol. 2024 Feb 2:S0210-5705(24)00025.
   PubMed     Abstract available
   
   
   January 2024
8. DOMENECH E, Ciudin A, Balibrea JM, Coll EE, et al
   Recommendations on the management of severe obesity in patients with inflammatory bowel disease of the Spanish Group on Crohn's Disease and Ulcerative Colitis (GETECCU), Spanish Society of Obesity (SEEDO), Spanish Association of Surgery (AEC) and Span
   Gastroenterol Hepatol. 2024 Jan 28:S0210-5705(23)00502.
   PubMed     Abstract available
   
   
   
9. PEREZ JP, Ortiz JE, Franco Moreno AI, Plaza Santos MDR, et al
   Influence of HLA-DQA1 *05 on the loss of response to anti-TNF treatment in inflammatory bowel disease. Spanish cohort of real clinical practice.
   Gastroenterol Hepatol. 2024 Jan 22:S0210-5705(24)00020.
   PubMed    
   
   
   
10. DEZA DC, Julian Gomara AB, Biota EC, Beltran B, et al
    IMPACT OF MESALAZINE ON THE RESPONSE TO COVID-19 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. RESULTS OF A PROSPECTIVE MULTICENTRE STUDY OF GETECCU (VACOVEII STUDY).
    Gastroenterol Hepatol. 2024 Jan 12:S0210-5705(24)00017.
    PubMed     Abstract available
    
    
    
11. MOYA MC, Gismero FM, Ferrer CS, Hernandez-Camba A, et al
    Position Statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on Sexuality and Inflammatory Bowel Disease.
    Gastroenterol Hepatol. 2024 Jan 11:S0210-5705(24)00019.
    PubMed     Abstract available
    
    
    
12. BALDERRAMO D, Yamamoto-Furusho J, Ponce de Leon E, de Maria J, et al
    Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study.
    Gastroenterol Hepatol. 2024;47:51-62.
    PubMed     Abstract available
    
    
    
13. GRAU G, Altadill A, Brunet-Mas E, Calvet X, et al
    Cyclosporine treatment for severe steroid refractory immune-mediated colitis in a patient with ulcerative colitis.
    Gastroenterol Hepatol. 2024;47:72-73.
    PubMed    
    
    
    December 2023
14. NONES RB, Miranda EF, Nardi Marcal G, Barbosa Barauna FDS, et al
    Infliximab serum concentrations in luminal Crohn's Disease and its relationship with disease activity: a multicentric cross-sectional study.
    Gastroenterol Hepatol. 2023 Dec 29:S0210-5705(23)00505.
    PubMed     Abstract available
    
    
    
15. CALDERON P, Nunez P, Nos P, Quera R, et al
    Personalized therapy in inflammatory bowel disease.
    Gastroenterol Hepatol. 2023 Dec 13:S0210-5705(23)00497.
    PubMed     Abstract available
    
    
    
16. BASTIDA G, Alvarez-Sotomayor D, Aguas M, Iborra M, et al
    Evaluation of tolerance to mercaptopurine in patients with inflammatory bowel disease and gastrointestinal intolerance to azathioprine.
    Gastroenterol Hepatol. 2023 Dec 8:S0210-5705(23)00491.
    PubMed     Abstract available
    
    
    
17. GARCIA-ALANIS M, Toapanta-Yanchapaxi L, Reyes-Velasquez A, Mancilla F, et al
    The interrelation between anxiety and quality of life among patients with ulcerative colitis in remission.
    Gastroenterol Hepatol. 2023;46:747-753.
    PubMed     Abstract available
    
    
    November 2023
18. DEZA DC, Julian Gomara AB, Biota EC, Beltran B, et al
    A BOOSTER DOSE OF SARS-CoV-2 VACCINE IMPROVES SUBOPTIMAL SEROCONVERSION RATES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. RESULTS OF A PROSPECTIVE MULTICENTER STUDY OF GETECCU (VACOVEII STUDY).
    Gastroenterol Hepatol. 2023 Nov 23:S0210-5705(23)00474.
    PubMed     Abstract available
    
    
    
19. PENA MEJIA LA, Ruiz Nino GV, Arteta Cueto AA
    Relation between histopathological findings, clinical severity, and the need of surgery in patients with Crohn's disease.
    Gastroenterol Hepatol. 2023 Nov 23:S0210-5705(23)00473.
    PubMed     Abstract available
    
    
    
20. MANUEL BENITEZ J, Suarez-Ferrer C, Calafat M, Baston-Rey I, et al
    Paediatric to adult transition programme in inflammatory bowel disease, why do we need it?
    Gastroenterol Hepatol. 2023 Nov 15:S0210-5705(23)00469.
    PubMed    
    
    
    
21. GONZALEZ-MUNOZA C, Gely C, Gordillo J, Bertoletti F, et al
    Duration of smoking cessation in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2023 Nov 15:S0210-5705(23)00470.
    PubMed     Abstract available
    
    
    October 2023
22. SILVA ACV, Tumelero TJ, Yamamoto DR, Truppel SK, et al
    Biological therapy, surgery, and hospitalization rates for inflammatory bowel disease: an observational Latin American comparative study between adults and pediatric patients.
    Gastroenterol Hepatol. 2023 Oct 25:S0210-5705(23)00452.
    PubMed     Abstract available
    
    
    
23. IZQUIERDO VP, Frias-Ordonez JS, Cuadros C, Vargas M, et al
    Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombian pediatric patients: Real world experience.
    Gastroenterol Hepatol. 2023 Oct 9:S0210-5705(23)00442.
    PubMed     Abstract available
    
    
    
24. PINERO G, Manosa M, Calafat M, Vayreda E, et al
    Mesalazine dose modification based on faecal calprotectin levels in patients with ulcerative colitis in clinical remission.
    Gastroenterol Hepatol. 2023 Oct 6:S0210-5705(23)00439.
    PubMed     Abstract available
    
    
    
25. IZQUIERDO VP, Frias-Ordonez JS, Banos FJ, Cuadros C, et al
    Colombian experience with the use of tofacitinib in severe acute ulcerative colitis: a case series study.
    Gastroenterol Hepatol. 2023 Oct 6:S0210-5705(23)00443.
    PubMed     Abstract available
    
    
    
26. LAO DOMINGUEZ FA, Fobelo Lozano MJ, Gutierrez Pizarraya A, Castro Fernandez M, et al
    Relationship between ustekinumab trough concentrations and both clinical and biological remission in patients with Crohn's disease.
    Gastroenterol Hepatol. 2023;46:631-632.
    PubMed    
    
    
    
27. FORTUNY M, Gutierrez-Rios L, Vayreda E, Manosa M, et al
    Tofacitinib for the treatment of inflammatory condition of the ileoanal pouch refractory to infliximab.
    Gastroenterol Hepatol. 2023;46:629-630.
    PubMed    
    
    
    August 2023
28. SERRANO DIAZ L, Iniesta Navalon C, Gomez Espin R, Nicolas De Prado I, et al
    Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: A retrospective cohort study.
    Gastroenterol Hepatol. 2023 Aug 18:S0210-5705(23)00392.
    PubMed     Abstract available
    
    
    
29. RIOS LG, Vayreda E, Calafat M, Canete F, et al
    Changes in the intensified regimen of infliximab in patients with inflammatory bowel disease in sustained remission. Reflections on a series of cases.
    Gastroenterol Hepatol. 2023 Aug 8:S0210-5705(23)00374.
    PubMed    
    
    
    
30. ARENAS A, Moreta MJ, Ordas I, Fernandez-Clotet A, et al
    De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice.
    Gastroenterol Hepatol. 2023 Aug 8:S0210-5705(23)00376.
    PubMed     Abstract available
    
    
    
31. DIAZ LS, Navalon CI, Espin RG, Prado IN, et al
    Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2023;46:504-511.
    PubMed     Abstract available
    
    
    June 2023
32. SUAREZ FERRER C, Martin-Arranz MD, Martin-Arranz E, Rodriguez Morata F, et al
    Current management of bowel failure due to Crohn's disease in Spain: Results of a GETECCU survey.
    Gastroenterol Hepatol. 2023;46:439-445.
    PubMed     Abstract available
    
    
    
33. NAVARRO-CORREAL E, Ibarz Casas A, Agustino Rodriguez S, Marin L, et al
    Knowledge, attitudes and behaviours on smoking cessation in nurses caring for patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2023;46:468-471.
    PubMed    
    
    
    May 2023
34. BENITO BM, Gisbert JP, Garcia Fraile Fraile LJ, Blandino AB, et al
    SEXUALLY TRANSMITTED INFECTIONS AS A DIFFERENTIAL DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE.
    Gastroenterol Hepatol. 2023 May 5:S0210-5705(23)00333.
    PubMed    
    
    
    
35. GONZALEZ-MARTINEZ A, Garcia IM, Quintas S, Chaparro M, et al
    Headache in patients with inflammatory bowel disease: Migraine prevalence according to the Migraine Screening-Questionnaire (MS-Q) and headache characteristics.
    Gastroenterol Hepatol. 2023 May 4:S0210-5705(23)00331.
    PubMed     Abstract available
    
    
    
36. MENG XF, Lin QY, Yin HL, Li ZQ, et al
    Magnetic resonance imaging for evaluation of bowel inflammation and disease activity in Crohn's disease: A systematic review and meta-analysis.
    Gastroenterol Hepatol. 2023;46:336-349.
    PubMed     Abstract available
    
    
    April 2023
37. PITARCH LG, Almela P, Nos P
    Leishmania infection in patients with Inflammatory Bowel Disease: case series and literature review.
    Gastroenterol Hepatol. 2023 Apr 13:S0210-5705(23)00074.
    PubMed     Abstract available
    
    
    
38. MORENO EN, Lopez Gonzalez J, Saez ML
    METASTATIC CROHN'S DISEASE WITH ESPLENIC AFECTATION: A VERY RARE CASE.
    Gastroenterol Hepatol. 2023 Apr 4:S0210-5705(23)00073.
    PubMed    
    
    
    
39. GARGALLO-PUYUELO CJ, Garcia-Mateo S, Martinez-Dominguez SJ, Gomollon F, et al
    Is the gender or age of the physician key to a good physician-patient with inflammatory bowel disease relationship?
    Gastroenterol Hepatol. 2023;46:261-265.
    PubMed     Abstract available
    
    
    
40. RAMOS L, Carrillo-Palau M, Alonso-Abreu I, Reygosa C, et al
    COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy: Fearless and with desire.
    Gastroenterol Hepatol. 2023;46:255-260.
    PubMed     Abstract available
    
    
    March 2023
41. CASTILLO-REGALADO E, Rios R, Arajol C, Gely C, et al
    Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy.
    Gastroenterol Hepatol. 2023;46:164-170.
    PubMed     Abstract available
    
    
    February 2023
42. CUFFI MS, Arias FA, Piudo AE, Vicens DG, et al
    Optimizing treatment of mild to moderate ulcerative colitis: CU-Forum Delphi Consensus.
    Gastroenterol Hepatol. 2023 Feb 15:S0210-5705(23)00034.
    PubMed     Abstract available
    
    
    January 2023
43. FUXMAN C, Sicilia B, Linares ME, Lopez SG, et al
    GADECCU 2022 Guideline for the treatment of Ulcerative Colitis. Adaptation and updating of the GETECCU 2020 Guideline.
    Gastroenterol Hepatol. 2023 Jan 30:S0210-5705(23)00014.
    PubMed     Abstract available
    
    
    
44. CASTANO LLANO R, Molina Meneses SP, Puerta JD, Escobar RM, et al
    Ileal reservoir-associated complications in ulcerative colitis versus familial adenomatous polyposis: Impact on patient quality of life.
    Gastroenterol Hepatol. 2023;46:39-47.
    PubMed     Abstract available
    
    
    December 2022
45. FERREIRO-IGLESIAS R, Piqueras M, Ricart E, Sempere L, et al
    Recommendations of the Spanish Group on Crohn's Disease and Ulcerative Colitis on the importance, screening and vaccination in inflammatory bowel disease patients.
    Gastroenterol Hepatol. 2022;45:805-818.
    PubMed     Abstract available
    
    
    
46. RUIZ-CERULLA A, Rodriguez-Alonso L, Rodriguez-Moranta F, Guardiola J, et al
    A high adalimumab induction dosing regimen achieves clinical and endoscopic remission in super-refractory ulcerative colitis.
    Gastroenterol Hepatol. 2022;45:780-781.
    PubMed    
    
    
    
47. PARRA-IZQUIERDO V, Sarmiento CF, Frias-Ordonez JS, Vargas M, et al
    Clinical and therapeutic characterisation of a multicentre cohort of patients with inflammatory bowel disease in Colombia.
    Gastroenterol Hepatol. 2022 Dec 1:S0210-5705(22)00278.
    PubMed     Abstract available
    
    
    November 2022
48. VICENS DG, Belinchon MR, Mateu PN, Elena Pejenaute Labari M, et al
    Spanish Society of Primary Care Physicians (SEMERGEN) and Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) survey on the management of patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2022 Nov 16:S0210-5705(22)00269.
    PubMed     Abstract available
    
    
    
49. QUERA R, Nunez P, Sicilia B, Flores L, et al
    Corticosteroids in Inflammatory Bowel Disease: Are they still a therapeutic option?
    Gastroenterol Hepatol. 2022 Nov 11. pii: S0210-5705(22)00263.
    PubMed     Abstract available
    
    
    
50. DAVIS GONZALEZ MR, Ballester MP, Romero-Gonzalez E, Sanchez-Pardo AM, et al
    Biological treatment interruption in inflammatory bowel disease: Motivation and predictive factors.
    Gastroenterol Hepatol. 2022 Nov 11:S0210-5705(22)00267.
    PubMed     Abstract available
    
    
    
51. PARRA-IZQUIERDO V, Frias-Ordonez JS, Marquez JR, Juliao-Banos F, et al
    Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombia: Real world experience.
    Gastroenterol Hepatol. 2022 Nov 10. pii: S0210-5705(22)00266.
    PubMed     Abstract available
    
    
    
52. JULIAO-BANOS F, Osorio L, Carvajal J, Mosquera-Klinger G, et al
    Clinical characteristics and treatment of perianal fistulising Crohn's disease in Colombia: Results of a multicentric registry.
    Gastroenterol Hepatol. 2022;45:690-696.
    PubMed     Abstract available
    
    
    
53. HERNANDEZ CAMBA A, Ramos L, Madrid Alvarez MB, Perez-Mendez L, et al
    Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection.
    Gastroenterol Hepatol. 2022;45:668-676.
    PubMed     Abstract available
    
    
    
54. DEL HOYO J, Millan M, Garrido-Marin A, Nos P, et al
    Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path toward the implementation of telemedicine in Spain?
    Gastroenterol Hepatol. 2022;45:697-705.
    PubMed     Abstract available
    
    
    
55. LADRON ABIA P, Minguez Sabater A, Saez Gonzalez E, Beltran Niclos B, et al
    Rescue therapy with oral cyclosporine after use of ustekinumab in ulcerative colitis resistant to multiple treatments.
    Gastroenterol Hepatol. 2022;45:735-736.
    PubMed    
    
    
    October 2022
56. CONSTANZA BAY M, Paulina Nunez F, Quera R, Yarur AJ, et al
    Current perspectives on pediatric inflammatory bowel disease focusing on Transitional care management. What should we consider?"
    Gastroenterol Hepatol. 2022 Oct 12. pii: S0210-5705(22)00229.
    PubMed     Abstract available
    
    
    
57. GELY C, Gordillo J, Bertoletti F, Gonzalez-Munoza C, et al
    Perception of the need for dietary advice and dietary modifications in inflammatory bowel disease patients.
    Gastroenterol Hepatol. 2022 Oct 12. pii: S0210-5705(22)00231.
    PubMed     Abstract available
    
    
    
58. LADRON ABIA P, Alonso N, Minguez Sabater A, Gimeno Torres M, et al
    The characteristics of the stricture, but not the ongoing treatment, could influence the outcome of endoscopic dilation in recurrent Crohn's disease.
    Gastroenterol Hepatol. 2022;45:614-620.
    PubMed     Abstract available
    
    
    
59. WAH-SUAREZ MI, Vazquez MAM, Bosques-Padilla FJ
    Inflammatory bowel disease: The role of commensal microbiome in immune regulation.
    Gastroenterol Hepatol. 2022;45:626-636.
    PubMed     Abstract available
    
    
    September 2022
60. NUNEZ L, Mesonero F, Rodriguez de Santiago E, Die J, et al
    High incidence of surgery and initiation of medical therapies after colectomy for ulcerative colitis or inflammatory bowel disease unclassified.
    Gastroenterol Hepatol. 2022 Sep 14. pii: S0210-5705(22)00216.
    PubMed     Abstract available
    
    
    
61. LATRAS-CORTES I, Alvarez PS, Prada MG, Sanz NC, et al
    Efficacy, persistence and optimization of ustekinumab in ulcerative colitis: clinical practice data.
    Gastroenterol Hepatol. 2022 Sep 13. pii: S0210-5705(22)00211.
    PubMed    
    
    
    August 2022
62. ALGABA A, Guerra I, Castro S, Bermejo F, et al
    SARS-CoV-2 infection in patients with inflammatory bowel disease in the second-third wave and its comparison with data of first wave of pandemic.
    Gastroenterol Hepatol. 2022;45:572-573.
    PubMed    
    
    
    
63. ROMERO RK, Magro DO, Queiroz NSF, Damiao AOMC, et al
    Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB).
    Gastroenterol Hepatol. 2022;45:499-506.
    PubMed     Abstract available
    
    
    May 2022
64. ROIG CA, Ferrer CS, Garcia JLR, Cordon JP, et al
    "Influence of biologic therapy on cardiovascular risk factors in patients with inflammatory bowel disease".
    Gastroenterol Hepatol. 2022 May 20. pii: S0210-5705(22)00156.
    PubMed     Abstract available
    
    
    
65. ALGABA A, Romero S, Granja A, Garza D, et al
    Serological Response To Vaccines Against Sars-Cov-2 In Patients With Inflammatory Bowel Disease.
    Gastroenterol Hepatol. 2022 May 20. pii: S0210-5705(22)00154.
    PubMed     Abstract available
    
    
    
66. LATRAS CORTES I, Sierra-Ausin M
    Tacrolimus plus ustekinumab in refractory ulcerative colitis.
    Gastroenterol Hepatol. 2022 May 13. pii: S0210-5705(22)00145.
    PubMed    
    
    
    
67. MARIA SR, Jesus B, Luis FS, Lara A, et al
    Incidence, and natural history of inflammatory bowel disease in Castilla y Leon: prospective and multicenter epidemiological study.
    Gastroenterol Hepatol. 2022 May 12. pii: S0210-5705(22)00139.
    PubMed     Abstract available
    
    
    
68. SURIA C, Bosca-Watts MM, Navarro P, Tosca J, et al
    Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives.
    Gastroenterol Hepatol. 2022;45:383-389.
    PubMed     Abstract available
    
    
    
69. RAMOS L, Ramos-Rodriguez J, Barreda R, Gutierrez-Nicolas F, et al
    Adherence to subcutaneous biologic treatment for inflammatory bowel disease.
    Gastroenterol Hepatol. 2022;45:335-341.
    PubMed     Abstract available
    
    
    April 2022
70. MERINO GALLEGO E, Gallardo Sanchez F
    Prevalence of extra-intestinal manifestations, risk factors and therapeutic risk factors and therapeutic management in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2022;45 Suppl 1:4-5.
    PubMed    
    
    
    
71. MARQUES-CAMI M, Garcia-Guinon A, Garreta J, Volta T, et al
    A 61-year-old patient with Crohn's disease and severe postoperative recurrence responding to JAK inhibitor ruxolitinib for polycythemia vera treatment.
    Gastroenterol Hepatol. 2022;45 Suppl 1:16-17.
    PubMed    
    
    
    
72. ESTEBANEZ FERRERO B, Ruiz Pardo J, Velasco Albendea FJ, Vidana Marquez E, et al
    Tuberculosis mimicking Crohn's disease and respiratory infection by COVID-19.
    Gastroenterol Hepatol. 2022;45 Suppl 1:13-15.
    PubMed    
    
    
    March 2022
73. NUNEZ F P, Quera R, Bay C, Thomson P, et al
    Fecal microbiota transplant, its usefulness beyond Clostridioides difficile in gastrointestinal diseases.
    Gastroenterol Hepatol. 2022;45:223-230.
    PubMed     Abstract available
    
    
    
74. MINGUEZ SABATER A, Conde Amiel I, Ladron Abia P, Martinez Delgado S, et al
    Characteristics and impact of sex in a cohort of patients with primary sclerosing cholangitis: Experience of a transplant center in the Mediterranean basin.
    Gastroenterol Hepatol. 2022;45:177-185.
    PubMed     Abstract available
    
    
    
75. MARIN-JIMENEZ I, Acosta MB, Esteve M, Castro-Laria L, et al
    Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study.
    Gastroenterol Hepatol. 2022;45:165-176.
    PubMed     Abstract available
    
    
    February 2022
76. REFAIE E, Garcia Mateo S, Martinez Dominguez SJ, Gargallo-Puyuelo CJ, et al
    Impact of the lockdown period due to the COVID-19 pandemic in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2022;45:114-122.
    PubMed     Abstract available
    
    
    
77. ROCHA HC, Vilela EG
    Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases.
    Gastroenterol Hepatol. 2022;45:83-90.
    PubMed     Abstract available
    
    
    January 2022
78. MEARIN F, Sans M, Balboa A
    Relevance and needs of Irritable Bowel Syndrome (IBS): comparison with Inflammatory Bowel Disease (IBD).
    Gastroenterol Hepatol. 2022 Jan 17. pii: S0210-5705(21)00332.
    PubMed     Abstract available
    
    
    
79. YEBRA CARMONA J, Poza Cordon J, Suarez Ferrer C, Martin Arranz E, et al
    Correlation between endoscopy and intestinal ultrasound for the evaluation of postoperative recurrence of Crohn's disease.
    Gastroenterol Hepatol. 2022;45:40-46.
    PubMed     Abstract available
    
    
    
80. ROJAS-FERIA M, Rodriguez-Fernandez M, Castro-Fernandez M, Suarez-Garcia E, et al
    Vedolizumab-induced cholestatic liver injury.
    Gastroenterol Hepatol. 2022;45:64-65.
    PubMed    
    
    
    December 2021
81. ZAVALA-SOLARES MR, Salazar-Salas L, Yamamoto-Furusho JK
    Validity and reliability of the health-related questionnaire IBDQ-32 in Mexican patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2021;44:711-718.
    PubMed     Abstract available
    
    
    November 2021
82. ZHANG X, Ma L, Zhang C, Hou B, et al
    Silencing LncRNA-DANCR attenuates inflammation and DSS-induced endothelial injury through miR-125b-5p.
    Gastroenterol Hepatol. 2021;44:644-653.
    PubMed     Abstract available
    
    
    October 2021
83. CALVET X, Carpio D, Rodriguez-Lago I, Garcia-Vicuna R, et al
    Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies.
    Gastroenterol Hepatol. 2021;44:587-598.
    PubMed     Abstract available
    
    
    August 2021
84. FERREIRO-IGLESIAS R, Hernandez-Camba A, Serrano Labajos R, Rodriguez-Lago I, et al
    SARS-CoV-2 vaccine acceptance among gastroenterologists and inflammatory bowel disease patients: VACUNEII project.
    Gastroenterol Hepatol. 2021 Aug 25. pii: S0210-5705(21)00246.
    PubMed     Abstract available
    
    
    
85. LIDON RV, Lopez SG, Roche PC, Miguel Boudet Barraca J, et al
    Translation into Spanish and validation of a short questionnaire to measure the control of inflammatory bowel disease from the patient s perspective: IBD-control, EII-control.
    Gastroenterol Hepatol. 2021 Aug 21. pii: S0210-5705(21)00243.
    PubMed     Abstract available
    
    
    
86. RODRIGUEZ-LAGO I, Mesonero F, Hijos-Mallada G, Canas M, et al
    SELF-MEDICATION WITH ANALGESICS REPORTED BY PATIENTS WITH ULCERATIVE COLITIS: AN ANONYMOUS SURVEY.
    Gastroenterol Hepatol. 2021 Aug 13. pii: S0210-5705(21)00227.
    PubMed     Abstract available
    
    
    
87. GENE M, Alguersuari A, Pons F, Minambres C, et al
    Serrated epithelial lesion with dysplasia as a precursor to small bowel carcinoma associated with Crohn's disease.
    Gastroenterol Hepatol. 2021;44:489-490.
    PubMed    
    
    
    July 2021
88. LORAS C, Manosa M, Andujar X, Sanchiz V, et al
    Recommendations of the spanish group on crohn's disease and ulcerative colitis (geteccu) on the treatment of strictures in crohn's disease.
    Gastroenterol Hepatol. 2021 Jul 15. pii: S0210-5705(21)00219.
    PubMed     Abstract available
    
    
    June 2021
89. HIJOS-MALLADA G, Sostres C, Gomollon F
    NSAIDs, gastrointestinal toxicity and Inflammatory Bowel Disease.
    Gastroenterol Hepatol. 2021 Jun 19. pii: S0210-5705(21)00201.
    PubMed     Abstract available
    
    
    
90. FORTUNY BAUZA M, Canete Pizarro F, Calm Salvans A, Calafat Sard M, et al
    Tofacitinib for the treatment of acute severe ulcerative colitis refractory to infliximab.
    Gastroenterol Hepatol. 2021 Jun 9. pii: S0210-5705(21)00188.
    PubMed    
    
    
    
91. GONZALEZ-MUNOZA C, Briones J, Sang Park H, Garcia-Planella E, et al
    Marginal zone lymphoma under anti-TNF treatment in Crohn disease.
    Gastroenterol Hepatol. 2021 Jun 9. pii: S0210-5705(21)00193.
    PubMed    
    
    
    
92. JULIAO-BANOS F, Arrubla M, Osorio L, Camargo J, et al
    Characterization and prevalence of extraintestinal manifestations in a cohort of patients with inflammatory intestinal disease in Medellin, Colombia.
    Gastroenterol Hepatol. 2021;44:398-404.
    PubMed     Abstract available
    
    
    May 2021
93. PEREZ DE ARCE E, Quera R, Beltran CJ, Madrid AM, et al
    Irritable Bowel Syndrome in Inflammatory Bowel Disease. Synergy in alterations of the gut-brain axis?
    Gastroenterol Hepatol. 2021 May 20. pii: S0210-5705(21)00143.
    PubMed     Abstract available
    
    
    
94. SEMPERE L, Bernabeu P, Cameo J, Gutierrez A, et al
    Evolution of the emotional impact in patients with early Inflammatory Bowel Disease during and after Covid-19 lockdown.
    Gastroenterol Hepatol. 2021 May 20. pii: S0210-5705(21)00145.
    PubMed    
    
    
    April 2021
95. GONZALEZ AE, Castillejo ON, Sainz IF, Lopez-Garcia A, et al
    Use of capsule endoscopy in Inflammatory Bowel Disease in clinical practice in Spain. Results from a national survey.
    Gastroenterol Hepatol. 2021 Apr 16. pii: S0210-5705(21)00110.
    PubMed     Abstract available
    
    
    
96. NUNEZ F P, Quera R, Sepulveda E, Simian D, et al
    Pregnancy in Inflammatory Bowel Disease: Experience of a Chilean cohort.
    Gastroenterol Hepatol. 2021;44:277-285.
    PubMed     Abstract available
    
    
    
97. DIAZ ALCAZAR MDM, Martin-Lagos Maldonado A, Garcia-Consuegra Ruiz-Aragon FM, Herrera Mercader MDC, et al
    Liver abscesses as an initial manifestation of Crohn's disease.
    Gastroenterol Hepatol. 2021;44:310-311.
    PubMed    
    
    
    
98. DE LOS MOZOS RUANO A, Casas Deza D, Calvo Galindo R, Solana Hidalgo MP, et al
    Methotrexate pneumonitis in a patient with Crohn's disease, during the COVID pandemic: An unusual clinical case and review of the literature.
    Gastroenterol Hepatol. 2021;44:302-303.
    PubMed    
    
    
    
99. HALLOUCH TOUTOUH S, Lazaro Saez M, Hernandez Martinez A
    Ustekinumab for prevention of postoperative recurrence: Our clinical experience.
    Gastroenterol Hepatol. 2021;44:296-297.
    PubMed    
    
    
    February 2021
100. SICILIA B, Vicente R, Arias L, Echarri A, et al
     Recommendations of the Spanish Working Group on Crohn's disease and ulcerative colitis (Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa - GETECCU) on dysplasia screening in inflammatory bowel disease patients.
     Gastroenterol Hepatol. 2021 Feb 13. pii: S0210-5705(21)00043.
     PubMed     Abstract available
     
     
     
101. CRISTINA SF, Angeles RRM, Maria SA, Luis RGJ, et al
     Nutricional Habits In Patients With Inflammatory Bowel Disease: Perception Of Patients And Health Professionals.
     Gastroenterol Hepatol. 2021 Feb 2. pii: S0210-5705(21)00014.
     PubMed    
     
     
     
102. RODRIGUEZ C, Elosua A, Prieto C, Perez E, et al
     COLECTOMY RATE IN ULCERATIVE COLITIS 15 YEARS AFTER DIAGNOSIS: Results from the 2001-2003 Navarra cohort.
     Gastroenterol Hepatol. 2021 Feb 2. pii: S0210-5705(21)00003.
     PubMed     Abstract available
     
     
     
103. PENNA FGC, Rosa RM, Pereira FH, Cunha PFS, et al
     Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease.
     Gastroenterol Hepatol. 2021;44:87-95.
     PubMed     Abstract available
     
     
     January 2021
104. NAVARRO-CORREAL E, Borruel N, Robles V, de Guise CH, et al
     Impact of the COVID-19 pandemic on the activity of advanced-practice nurses on a reference unit for inflammatory bowel disease.
     Gastroenterol Hepatol. 2021 Jan 27. pii: S0210-5705(21)00005.
     PubMed     Abstract available
     
     
     
105. BLASCO PATINO F, Nicolae MV, Navarro E
     Acute submandibular sialadenitis in a patient with Crohn's disease being treated with infliximab.
     Gastroenterol Hepatol. 2021;44:49-50.
     PubMed    
     
     
     December 2020
106. MUNOZ F, Ripolles T, Poza Cordon J, de Las Heras Paez de la Cadena B, et al
     Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of abdominal ultrasound in inflammatory bowel disease.
     Gastroenterol Hepatol. 2020 Dec 11. pii: S0210-5705(20)30214.
     PubMed     Abstract available
     
     
     November 2020
107. RUBIANO MR, Medina GR, Perez-Riveros ED, Panqueva RDPL, et al
     Proctitis is not always ulcerative colitis.
     Gastroenterol Hepatol. 2020 Nov 25. pii: S0210-5705(20)30441.
     PubMed    
     
     
     
108. QUERA R, Simian D, Flores L, Ibanez P, et al
     IMPACT OF THE COVID-19 PANDEMIC ON TREATMENT ADHERENCE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: EXPERIENCE OF A TERTIARY HOSPITAL IN CHILE.
     Gastroenterol Hepatol. 2020 Nov 21. pii: S0210-5705(20)30438.
     PubMed    
     
     
     
109. QUERA R, Pizarro G, Simian D, Ibanez P, et al
     Impact of COVID-19 on a cohort of patients with inflammatory bowel disease at a specialised centre in Chile.
     Gastroenterol Hepatol. 2020 Nov 20. pii: S0210-5705(20)30431.
     PubMed    
     
     
     
110. LADRON ABIA P, Alcala Vicente C, Martinez Delgado S, Bastida Paz G, et al
     Fingolimod-induced remission in a patient with ulcerative colitis and multiple sclerosis.
     Gastroenterol Hepatol. 2020 Nov 13. pii: S0210-5705(20)30364.
     PubMed    
     
     
     
111. MINGUEZ SABATER A, Martinez Delgado S, Ladron Abia P, Bastida G, et al
     Skin injuries associated with biological therapy in inflammatory bowel disease: beyond psoriasis.
     Gastroenterol Hepatol. 2020 Nov 11. pii: S0210-5705(20)30378.
     PubMed    
     
     
     
112. LUCAS RAMOS J, Suarez Ferrer C, Poza Cordon J, Sanchez Azofra M, et al
     Optimization of azathioprine dose in combined treatment with anti-TNF-alpha in inflammatory bowel disease.
     Gastroenterol Hepatol. 2020 Nov 7. pii: S0210-5705(20)30387.
     PubMed     Abstract available
     
     
     
113. PEREZ DE ARCE E, Quera R, Nunez P, Simian D, et al
     Management of acute severe ulcerative colitis in chile: Experience of a multidisciplinary team.
     Gastroenterol Hepatol. 2020 Nov 6. pii: S0210-5705(20)30400.
     PubMed    
     
     
     October 2020
114. QUERA R, Simian D, Nunez P, Flores L, et al
     Are patients with inflammatory bowel disease receiving adequate immunisation?
     Gastroenterol Hepatol. 2020 Oct 29. pii: S0210-5705(20)30303.
     PubMed     Abstract available
     
     
     
115. EZQUERRA A, Resina E, Montes A, Alvarez-Male T, et al
     Pericardial effusion associated with mesalamine treatment in a patient with ulcerative colitis.
     Gastroenterol Hepatol. 2020 Oct 20. pii: S0210-5705(20)30377.
     PubMed    
     
     
     
116. NUNEZ P, Garcia Mateo S, Quera R, Gomollon F, et al
     Inflammatory bowel disease and the risk of cardiovascular diseases.
     Gastroenterol Hepatol. 2020 Oct 20. pii: S0210-5705(20)30375.
     PubMed     Abstract available
     
     
     
117. NUNEZ F P, Quera R, Simian D, Flores L, et al
     Infliximab in inflammatory bowel disease. Is premedication necessary?
     Gastroenterol Hepatol. 2020 Oct 20. pii: S0210-5705(20)30362.
     PubMed     Abstract available
     
     
     
118. NUNEZ F P, Mahadevan U, Quera R, Bay C, et al
     Treat-to-target approach in the management of inflammatory Bowel disease.
     Gastroenterol Hepatol. 2020 Oct 15. pii: S0210-5705(20)30318.
     PubMed     Abstract available
     
     
     
119. LOPEZ GONZALEZ J, Hernandez Martinez A, Lazaro Saez M, Vega Saenz JL, et al
     Experience with tofacitinib in patients with refractary ulcerative colitis.
     Gastroenterol Hepatol. 2020 Oct 10. pii: S0210-5705(20)30309.
     PubMed    
     
     
     
120. GARCIA-ALANIS M, Quiroz-Casian L, Castaneda-Gonzalez H, Arguelles-Castro P, et al
     Prevalence of mental disorder and impact on quality of life in inflammatory bowel disease.
     Gastroenterol Hepatol. 2020 Oct 8. pii: S0210-5705(20)30304.
     PubMed     Abstract available
     
     
     
121. DEL HOYO J, Aguas M
     Implementing telemedicine in inflammatory bowel disease: Is COVID-19 the definitive trigger?
     Gastroenterol Hepatol. 2020;43:415-417.
     PubMed    
     
     
     April 2020
122. POUS S, Frasson M, Jimenez R, Pamies J, et al
     Relevance of dynamic studies with magnetic resonance enterography in Crohn's disease.
     Gastroenterol Hepatol. 2020;43:179-187.
     PubMed     Abstract available
     
     
     March 2020
123. CASAS DEZA D, Garcia Lopez S, Lafuente Blasco M, Vicente Lidon R, et al
     Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohort.
     Gastroenterol Hepatol. 2020;43:126-132.
     PubMed     Abstract available
     
     
     January 2020
124. GELY C, Marin L, Gordillo J, Manosa M, et al
     Impact of pain associated with the subcutaneous administration of adalimumab.
     Gastroenterol Hepatol. 2020;43:9-13.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.